In HAE, we are advancing multiple drug candidates into Phase 1 clinical trials, with additional program candidates in preclinical development. KVD900 is one of these candidates, and is expected to enter a Phase 2 clinical trial for on-demand treatment of acute HAE attacks in late 2018. In DME, our most advanced compound, an intravitreally administered plasma kallikrein inhibitor known as KVD001, has successfully completed its first-in-human study in patients with DME and began a Phase 2 clinical trial in 2017. We anticipate data from this trial in the second half of 2019. In October 2017, we entered into a collaboration agreement with Merck for KVD001 as well as future oral DME compounds based upon plasma kallikrein inhibition.
We have an R&D team with an established track record in the pharmaceutical development of small molecule protease inhibitors, world-leading expertise in the role of plasma kallikrein in disease, and a management team with the capability to bring small molecules through the clinic to commercialization.
Our offices and labs are in Cambridge, MA and Salisbury, UK.